Q/C Technologies (QCLS) Q4 2024 earnings summary

Executive summary

• The company completed a major recapitalization, issuing Series F-1 and Series G Preferred Stock and related warrants, raising $13.9 million in net proceeds in 2024.

• A 1-for-30 reverse stock split and an increase in authorized shares to 250 million were executed.

• The company changed its name to TNF Pharmaceuticals, Inc. and reincorporated in Delaware.

• The company remains pre-revenue, focused on developing Isomyosamine and Supera-CBD.

Financial highlights

• Net loss attributable to shareholders was $27.2 million for 2024, compared to $8.2 million in 2023.

• Operating expenses decreased 40.6% year-over-year to $10.2 million.

• Research and development expenses fell 56.3% to $3.4 million, reflecting completion of key studies.

• Cash and marketable securities totaled $8.5 million at year-end 2024, down from $4.9 million in 2023.

• Working capital was $2.7 million and stockholders’ equity was $9.8 million as of December 31, 2024.

• No revenue was generated in 2024 or 2023.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as clinical development progresses.

• Additional capital will be required to fund operations and clinical trials over the next 12 months.

• The company is evaluating financing options, including debt and equity offerings.